TCA IR 40

DRUG3 trials

Sponsors

Pacira Pharmaceuticals, Inc

Conditions

Osteoarthritis of the Knee

Phase 2

Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee

CompletedNCT01487200

Pacira Pharmaceuticals, IncOsteoarthritis of the Knee

Start: 2012-07-31End: 2012-11-30Updated: 2024-01-24

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

CompletedNCT02637323

Pacira Pharmaceuticals, IncOsteoarthritis of the Knee

Start: 2015-11-30End: 2016-09-30Updated: 2024-01-24

Phase 3

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

CompletedNCT02357459

Pacira Pharmaceuticals, IncOsteoarthritis of the Knee

Start: 2015-01-31End: 2016-01-31Updated: 2024-01-24

Related Papers

Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain Scales

Pain and Therapy2021-11-176 citations

Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials.

2019-05-0710 citations

Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.

2019-04-0924 citations